Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
The Latest on: Flu vaccine
via Google News
The Latest on: Flu vaccine
- “The Great Influenza” author John M....on May 29, 2020 at 6:04 pm
The Great Influenza” author John M. Barry compares the COVID-19 pandemic with the deadly 1918 Spanish Flu outbreak and explains how American troops carried that earlier virus into Europe during World ...
- Jason Kenney Keeps Calling COVID-19 ‘Influenza.’ Here’s Why He’s Wrong.on May 29, 2020 at 1:52 pm
It would be understandable if you think Alberta Premier Jason Kenney really wants people to believe that COVID-19 is like “strains of influenza” we’ve seen before. “One thing I think we’re learning, ...
- Influenza Vaccine Market Clinical Research Analysis 2020 to 2026: Sanofi, Altimmune, BionVax, FluGen, Folia Biotechon May 29, 2020 at 6:53 am
Global Influenza Vaccine Market Insights, Forecast To 2026: The report discusses many vital industry facets that influence the "Global Influenza Vaccine Market" industry acutely which includes ...
- How the Influenza Pandemic Popularized Lemonson May 28, 2020 at 3:15 pm
There was pretty Chamber of Commerce spokesperson Marie Cooney October 23 Los Angeles Herald, between an accounting of influenza deaths and an accounting of war casualties, demonstrating the technique ...
- TSRL, Inc. awarded $3M NIH grant to continue development of microneedle patch for treatment of influenzaon May 28, 2020 at 5:12 am
TSRL, Inc., announces the continued development of a transdermal delivery system of zanamivir (Relenza®), an inhalation drug product ...
- Exclusive: GSK Says Science Does Not Link Pandemic H1N1 Flu Vaccine to Sleep Disorderon May 28, 2020 at 4:14 am
A nurse holds a bottle of the Pandemrix H1N1 flu vaccine (R) and a bottle of the vaccine's adjuvant (L) at a health centre in Burgos in this November 16, 2009 . REUTERS/Felix Ordonez/FilesReuters ...
- Seaweed Extract Offers Hope for Influenza Aon May 28, 2020 at 12:45 am
Australian scientists have revealed that a natural compound found in seaweed may reduce the effects of severe cases of Influenza A.
- Influenza Vaccine Market | Industry Size, Growth Rate and Global Analysis 2020-2026on May 28, 2020 at 12:20 am
Influenza Vaccine Market 2020 Global Industry Analysis with Forecast To 2026 is latest depth analysis report on ...
- Pharmacies Gearing Up For Flu Vaccine Seasonon May 27, 2020 at 1:10 pm
News broke this week about pharmacy chains gearing up for a heavy flu season. For context, Rite Aid (NYSE:RAD) is planning on ordering 40% more doses than normal seasons require to meet demand.
- The vaccine we're testing in Australia is based on a flu shot. Here's how it could work against coronaviruson May 27, 2020 at 5:22 am
CoV2373 and is from a US biotech company, Novavax. The trial will be carried out across Melbourne and Brisbane, and is the first human trial of a vaccine ...
via Bing News